CD8A and neoplasm: As determined by scRNA-seq analysis and supported with flow cytometry and immunofluorescence-based tissue staining, the combination therapy promoted the infiltration and activation of CD8+ T cells in the tumor parenchyma, reshaped and repolarized M2 macrophage phenotypes, and promoted the remodeling of the ECM.